CINNASIL Drug Patent Profile
✉ Email this page to a colleague
When do Cinnasil patents expire, and when can generic versions of Cinnasil launch?
Cinnasil is a drug marketed by Panray and is included in one NDA.
The generic ingredient in CINNASIL is rescinnamine. There is one drug master file entry for this compound. Additional details are available on the rescinnamine profile page.
Summary for CINNASIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 33 |
Patent Applications: | 1,184 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CINNASIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CINNASIL
US Patents and Regulatory Information for CINNASIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Panray | CINNASIL | rescinnamine | CAPSULE;ORAL | 084736-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |